sam: glaxo has already decided they are going to get the two companies split, and glaxo doesn't have any more to do after that. j&j, by biggest question is why not move out of medical devices? put that in a separate company, too. lisa: why now? sam: as i said, i am really happy they are doing it. maybe it has to do with the issue of litigation, but honestly, each of these businesses is now definitely big enough to be very significant players. lisa: also the idea that johnson & johnson has the inferior shot to combat covid, the idea that it's inoculation was not as successful as others from moderna and pfizer. how much does mrna development, the idea of trying to get on the cutting edge of biopharmaceuticals part of this as well? sam: i really don't think they are related. the j&j vaccine, the reason it not showing the same level of efficacy is simply because it is a single shot. everybody talked about it or get it was the right thing to do perhaps at the time for them, get this vaccine out, single shot, prevent as many deaths and hospitalizations as possible. but you can't just get a

. >>> welcome back vir biotechnology and glaxo smith klein announcing today they will sell $1 billion worth of their covid-19 antibody drug to the u.s. government vir stock is down nearly 40% in two months as merck and pfizer get ready to come out with their own anti-viral drugs to fight covid-19 so joining us now is george, the ceo of vir biotechnology along with our own meg tirrell meg, over to you. >> dom, thank. george, it is nice to see you. thank you for joining us today on news this billion dollars worth of contracts with the u.s. government dom mentioned the stock move over the last two months i think what a lot of investors are wondering about the antibody drugs now is as the anti-viral pills are working their way through the fda what role do your drugs play, the antibody drugs, when we have easier to take pills for covid >> that's a great question i think the important thing to remember is we had good data last week on an intramusk collar application. we did a clinical trial comparing a im single inject versus the iv administration of the antibodies patients will have a choi

. >> i know that you have committed to the one bayer, but i look at what ge has done, glaxo, why are you still so convinced of the model that you have at the moment? >> over the last 20 years, we have pursued a strategy of becoming a multi-business business. we have a lot of businesses that are not driven by science. the areas that we've been focusing on is life-sciences. if you look at our portfolio today, we are active in three businesses, pharmaceutical, crop science, and consumer health business. all of them are informed by the life-sciences platform. we see significant advantages of running those three businesses together under one roof. matt: that was the ceo of bayer. let's get to something that caught my eye. the shares of john deere. they are climbing after the company and its workers ended a month-long strike at u.s. plants. the deal will increase pay and boost retirement benefits over a six-year period. the work stoppage took some 10,000 workers off the line and threw several of their businesses into turmoil. the contract increases were worker wages by 10% in the first yea

why do you bring up glaxo, though >> they were saying people do not see the great growth in our farmo. the only was to draw attention to is the. >> this one is not clear >> you have some excitement in every division. >> true. just like ge, this is going to take time. >> why do you think -- >> similar to ge it will be two years before -- >> medical devices have been bad because of covid that can snap back let's not forget the talc litigation is with consumer product, that litigation has been horrendous. it's not all done in fair weather, j&j, but they have a great cancer franchise that people don't talk enough about they do a lot of good drugs. >> but then the pure group will be merck, pfizer, all the ones we still talk about it with, but obviously still a pure play, and the consumer products will nestle and p & g colgate? where do you put it? >> colgate is such a long-term winner, and i just think in the end you should try to merge it with one of those companies. >> you do? speculation of a merge spin of this kind -- that's not i don't think in the cards at this point, but this will b

segment on an existing show and june 27, '06, pfizer announced they sold the consumer business to j&j and glaxo was bidding for it that was going to be the deal of the century. do i buy it? absolutely j&j, not an expensive stock given the market multiple where it probably should be and i think probably doing this because these companies independently can be a bit more nimble running themselves by themselves opposed to the umbrella and the fact it's $179 stock in mid august i think. >> i thought you were going to say "fast money" spun off into a show and then the valuation has really -- is that what you meant? >> i teed you up for that, dude. we were spun off the spinoff happened got a show i believe in september of '06 did it for a week and almost 15 years later. >> cnbc conglomerate. >> back into the market zone as if we poached you out of the spinoff. something like that happening here >> i love it. >> doesn't really matter energy is worst sector today posting the third weekly loss in a row and oil's pain is not a gain for ev ds tesla extended the losses today. musk sold more than $600 millio

glaxo smith-kline will deliver them with the option to purchase more through march this thriving shares and particularly the smaller company, this morning, jfk there not moving too much on the news and this follows a lot of purchases in the past few weeks of covid drugs they appear to be beefing up the arsenal of covid, cases head to rise into winter in the last months, the number of deals they struck they're yellow, the anti-viral pills in white pfizer is expecting to have a deal announced this week up to $5 billion for the u.s. government it's a trend it's interesting to see the government buying up these medicines as they are trying to get these vaccinated >> mccolllock. meg tirrell. thank you. appreciate it. when we come back, a lot more on "squawk," former time warner chairman ceo jeff bewkes and james andrew miller will join us the future, let's show you where things stand nasdaq looking to open higher about 22 points higher "squawk" returns after this. so, you want evs, you have come to the right place. is that tom brady? yeah. he comes in to recharge, get software updates. you k

for glaxo voters, now, we have been able to track the difference in air quality and actually we are quite fortunate the majority of the time we do actually have some really good nice quality air. however, you can easily see the pattern emerging, even over this week there were busy periods, say, at eight o'clock in the morning at the end of the day now in the street is nearly at standstill that the air quality is really affected.— really affected. that is really important — really affected. that is really important because _ really affected. that is really important because there - really affected. that is really important because there is l really affected. that is really i important because there is the really affected. that is really - important because there is the time is my children are making their journey to and from school and obviously we need to be really mindful and very educated, i suppose, about what that quality of air and the environment that they are walking to school in dorset and impacts on their health.— impacts on their health. because i will sa i impacts on thei